U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C54H92O23
Molecular Weight 1109.2945
Optical Activity UNSPECIFIED
Defined Stereocenters 30 / 30
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GINSENOSIDE RB1

SMILES

[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O

InChI

InChIKey=GZYPWOGIYAIIPV-JBDTYSNRSA-N
InChI=1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1

HIDE SMILES / InChI

Molecular Formula C54H92O23
Molecular Weight 1109.2945
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 30 / 30
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb1/ https://www.ncbi.nlm.nih.gov/pubmed/25120573

Ginsenoside Rb1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, orexigenic, and stimulatory activities. In animal models, ginsenoside Rb1 increases motor activity, food intake, and skeletal muscle ATP content, improving energy metabolism. Ginsenoside Rb1 also downregulates expression of toll-like receptor 4 (TLR4) and TNF-α in animal models of sepsis, protecting against liver and lung damage. Additionally, ginsenoside Rb1 inhibits glucose-induced neurotoxicity by preventing GSK-3β-stimulated CHOP induction. This compound also activates Nrf2 and increases expression of heme oxygenase 1 (HO-1), suppressing oxidative stress in vitro. Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis. Ginsenoside Rb1 is a component of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:

CNS Activity

Curator's Comment: Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of the ginsenosides Rg1 and Rb1 on morphine-induced hyperactivity and reinforcement in mice.
1998 May
Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice.
1998 May
Inhibition by ginsenosides Rb1 and Rg1 of cocaine-induced hyperactivity, conditioned place preference, and postsynaptic dopamine receptor supersensitivity in mice.
1999 Jul
Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells.
2003 Jan
Calcium-independent CaMKII activity is involved in ginsenoside Rb1-mediated neuronal recovery after hypoxic damage.
2005 Jan 14
Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes.
2005 May
Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect.
2005 Oct
Efficient induction of ginsenoside biosynthesis and alteration of ginsenoside heterogeneity in cell cultures of Panax notoginseng by using chemically synthesized 2-hydroxyethyl jasmonate.
2006 Apr
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006 Nov
Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery.
2007 Jul 19
Comparison of ginsenosides Rg1 and Rb1 for their effects on improving scopolamine-induced learning and memory impairment in mice.
2010 Dec
Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells.
2010 Jan 1
Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components.
2010 Jul 20
Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations.
2012 Aug 20
Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways.
2012 May
Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies.
2014
Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in Neuro-2a cells.
2014
Dissecting active ingredients of Chinese medicine by content-weighted ingredient-target network.
2014 Jul
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice.
2014 Oct
Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro.
2014 Oct
Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
2015 Feb
Patents

Patents

Sample Use Guides

To treat vascular dementia: Fufangdanshen tablet contains ginsenoside Rb1 3.03mg, as well as tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rg1 2.73mg. 3 tablets per time, 3 times per day for 24 weeks
Route of Administration: Oral
Compared with the control group, GS-Rb1 from 2.5 to 40 uM incubation increased viability of neonatal rat cardiomyocytes from 31.7%±1.3% to 53.3%±1.7%.
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:15:47 GMT 2023
Edited
by admin
on Sat Dec 16 02:15:47 GMT 2023
Record UNII
7413S0WMH6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GINSENOSIDE RB1
Common Name English
GYNOSAPONIN C
Common Name English
NOTOGINSENOSIDE RB1
Common Name English
GYPENOSIDE III
Common Name English
.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,12.BETA.)-20-((6-O-.BETA.-D-GLUCOPYRANOSYL-.BETA.-D-GLUCOPYRANOSYL)OXY)-12-HYDROXYDAMMAR-24-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANOSYL-
Systematic Name English
NSC-310103
Code English
GINSENOSIDE RB1 [USP-RS]
Common Name English
ARASAPONIN E1
Common Name English
GINSENOSIDE RB1 (CONSTITUENT OF AMERICAN GINSENG, ASIAN GINSENG, AND TIENCHI GINSENG) [DSC]
Common Name English
SANCHINOSIDE RB1
Common Name English
Ginsenoside Rb1 [WHO-DD]
Common Name English
PANAXOSIDE RB1
Common Name English
SANCHINOSIDE E1
Common Name English
Code System Code Type Description
WIKIPEDIA
Ginsenoside Rb1
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
FDA UNII
7413S0WMH6
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
NSC
310103
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
DRUG BANK
DB06749
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
PUBCHEM
9898279
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
CAS
41753-43-9
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
RS_ITEM_NUM
1291661
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID401316929
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
CHEBI
67989
Created by admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
PARENT -> CONSTITUENT ALWAYS PRESENT
USP